title: Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist.
abstract: The inhibitor of apoptosis gene family member Survivin is highly expressed in most tumors, and appears to be a promising target for cancer therapy. Although a variety of Survivin antagonists have been shown to induce apoptosis in malignant cells, the potential utility of these agents is limited by inefficient delivery and cell impermeability. We generated recombinant fusion proteins containing the TAT protein transduction domain and either wild-type Survivin (TAT-Surv-WT) or a dominant-negative mutant (TAT-Surv-T34A). The TAT-Surv proteins were purified by sequential affinity and ion-exchange chromatography, and at 30 nM concentration demonstrated rapid entry into cells at 30 min. Whereas TAT-Surv-WT had minimal effect on YUSAC2 or WM793 melanoma cells, TAT-Surv-T34A induced cell detachment, DNA fragmentation, caspase-3 activation and mitochondrial release of apoptosis-inducing factor at low microM concentrations. Intraperitoneal (i.p.) injection of mice bearing subcutaneous YUSAC2 xenografts with TAT-Surv-T34A (10 mg/kg) was associated with rapid tumor accumulation at 1 h, and increased tumor cell apoptosis and aberrant nuclei formation in situ. Repeated i.p. injection of TAT-Surv-T34A resulted in a 40-50% reduction in growth and mass of established tumors, compared to those similarly injected with saline buffer or TAT-Surv-WT. These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist.
authors.affiliation: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
authors.forename: H
authors.initials: H
authors.lastname: Yan
authors.forename: J
authors.initials: J
authors.lastname: Thomas
authors.forename: T
authors.initials: T
authors.lastname: Liu
authors.forename: D
authors.initials: D
authors.lastname: Raj
authors.forename: N
authors.initials: N
authors.lastname: London
authors.forename: T
authors.initials: T
authors.lastname: Tandeski
authors.forename: S A
authors.initials: SA
authors.lastname: Leachman
authors.forename: R M
authors.initials: RM
authors.lastname: Lee
authors.forename: D
authors.initials: D
authors.lastname: Grossman
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology*; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D004591:Electrophoresis, Polyacrylamide Gel; D005434:Flow Cytometry; D015696:Gene Products, tat / Q000627:therapeutic use*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008545:Melanoma / Q000473:pathology* / Q000628:therapy*; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009374:Neoplasms, Experimental / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D000077022:Survivin; D014161:Transduction, Genetic
chemical_list: C107489:BIRC5 protein, human; D015696:Gene Products, tat; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D011993:Recombinant Fusion Proteins; D000077022:Survivin